Hyperkalaemia (raised serum potassium)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
≥ 6.5 mmol/L, or ≥ 6.0 with ECG changes, malaise or acute kidney injury: emergency department
- No tests in the community: refer to the emergency department (continuous cardiac monitoring).
- Do an ECG if possible without delaying transfer.
6.0 to 6.4 mmol/L, patient well: recheck within 24 hours
Within 24 hours
- Serum electrolytes (repeat serum potassium)
- Serum creatinine with eGFR
- Bicarbonate
- Plasma glucose
- FBC (if the repeat serum potassium remains high with no obvious cause)if needednon-French guidelineHyperkalaemia with normal renal function and ECG, or known haematological disease: thrombocytosis, hyperleucocytosis or polycythaemia can cause a false hyperkalaemia [1,2].
- Draw blood from the antecubital fossa without clenching the fist, tourniquet released as soon as the vein is punctured (less than a minute); transport quickly to the laboratory, without refrigeration; note the time of sampling. If spurious hyperkalaemia is suspected: request serum potassium on serum and on plasma (heparinised tube) drawn at the same time.
- ECG the same day.
5.5 to 5.9 mmol/L: recheck within 3 days and investigate
Within 3 days
- Serum electrolytes (repeat serum potassium)
- Serum creatinine with eGFR
- Bicarbonate
- Plasma glucose
- FBC (if the repeat serum potassium remains high with no obvious cause)if needednon-French guidelinePersistent hyperkalaemia with normal renal function and ECG, or known haematological disease: thrombocytosis, hyperleucocytosis or polycythaemia can cause a false hyperkalaemia [1,2].
- 8 am serum cortisol (if hyperkalaemia confirmed with no renal failure or causative drug)if needednon-French guidelineUnexplained true hyperkalaemia, all the more so with hyponatraemia, asthenia, weight loss, hypotension or melanoderma: Addison's disease (primary adrenal insufficiency) is one cause [1].
- Draw blood without clenching the fist, tourniquet released as soon as the vein is punctured; transport quickly, without refrigeration; note the time of sampling.
Sources (12)
- UK Kidney Association. Clinical practice guideline: treatment of acute hyperkalaemia in adults (management of hyperkalaemia in adults). Version initiale juillet 2020, mises à jour octobre 2023 et juillet 2026.
- Clase CM, Carrero JJ, Ellison DH, et al. ; KDIGO Controversies Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42-61.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314 (section 3.11, tableau 28).
- Kim MJ, Valerio C, Knobloch GK. Potassium Disorders: Hypokalemia and Hyperkalemia. Am Fam Physician. 2023;107(1):59-70A.
- Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care, 5e édition. Melbourne : Kidney Health Australia ; juillet 2024 (section « Hyperkalaemia », p. 64-65).
- Haute Autorité de santé. Guide du parcours de soins – Maladie rénale chronique de l'adulte (MRC). Validé en juillet 2021, mis à jour en septembre 2023.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit SPIRONOLACTONE VIATRIS 75 mg, comprimé pelliculé, rubrique 4.8.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit PENTAMIDINE TILLOMED 300 mg, poudre pour solution injectable, rubrique 4.8.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit PRESTOLE (périndopril), gélule, rubrique 4.5.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit CONFEROPORT 1 mg (tacrolimus), gélule à libération prolongée, rubrique 4.8.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit FLUCONAZOLE EVOLUGEN 50 mg, gélule, rubrique 4.8.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit ITRACONAZOLE VIATRIS 100 mg, gélule, rubrique 4.8.